Skip to main content
. 2022 Jul 11;10(7):1661. doi: 10.3390/biomedicines10071661

Figure 2.

Figure 2

Semaglutide reduces body weight and improves hyperglycemia in db/db UNx-ReninAAV mice. (A) Body weight. (B) Fed blood glucose levels. (C) Terminal HbA1c levels. (D) Terminal plasma insulin concentrations. Semaglutide monotherapy (30 nmol/kg, s.c., q.d., n = 15) and combination treatment with lisinopril (30 mg/kg, p.o. q.d., n = 14) was performed for 11 weeks in db/db UNx-ReninAAV mice. Vehicle-dosed (s.c., q.d.) db/db UNx-ReninAAV mice (n = 15) served as controls. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle-dosed db/db UNx-ReninAAV mice (Dunnett’s test one-factor/two-factor linear model with interaction).